Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did someone mention SSQQEEEEZZEE. GEM RULES and they WANT $$$2+$$$, Nasdaq. JMHFO...GLTA...
Yes, the Science many have documented should shine. A well thought out PR and presentation of the Data, targeted to the successes this time, would be nice. Immediate news of an EUA application after data release would be nicer and news of Partnership or other Deal would be Nicest. I think they realize the Interim data could have been presented in a MUCH better light. ...GLTA...
VOLUME 3X+, dont let the Shorts out easy. Small buys at a raising Ask by Many will do, it. Hell, Buy because it's a smart investment. IMHFO.
GEM is NOT selling per earlier post link, they know where this will go. They just put MORE $$$ in. Possible Nasdaq move and/or Merge/re;Merge... All, IMHFO...GLTA...
Looks like RLF might be going to the Nasdaq in the ACER shell IF it does not join into the NRXP deal. ASAP/FAST/BEFORE the DATA so we can get INSTITUTIONAL INVESTMENTS. IMO...
It will have the PATENT for formulations of RLF-100/VIP with the Inhaler expertise and IP of AdviTa. Seems a sealed deal now with the Volume and PRs...
The big OS @RLF but much smaller Float could SQQEEEEZE. IMO. Alot of penny shorts here. GEM Rules...
...GLTA...
A combination of products and logistics and management and sales, etc.
But also a Real drug company needs a future so, NRX-100/NRX-101, the syrup urine drug from ACER, RLF-100 /VIP now with strong Inhaler portfolio. Then this has real legs. Confirmed Patent. GEM has the Votes and then Bonuses for all, we'll be along for the ride...
The NRXP IPO - re;merge is a done deal from what those folks have Pr'd. The RLF-100 Patent is under RLF.sw/RLFTF. GEM wants their RETURN and NO STRINGS, IMO...GLTA...
Reverse Merge/with ACER was the term used here. GEM has large/Huge investments in Both NRX and at RLF. They want Institutional Investors from Nasdaq when or soon after Data is released, IMO. My crystal ball says they list as NRXP and ACER(RLF) then merge there again. GEM has the shares to control the Vote here...GLTA...
Lets all hope MF is TOO BUSY and SMART to answer these type of Emails with anything of substance. I'm very Glad he didnt and am sorry You wasted his time. Hope it was a secretary. Obviously any company will NOT give out any info that is NOT Public. DUH...
"Investors do Not RUN the company, they can just Buy-Hold-Sell the Stock..."
Dont worry, be Happy. Liberty caps help...GLTA...
Looks like RLF is going to the Nasdaq in the ACER shell. ASAP/FAST/BEFORE the DATA so we can get INSTITUTIONAL INVESTMEN. IMO... It will have the PATENT for formulations of RLF-100/VIP with the Inhaler expertise and IP of AdviTa. Seems a sealed deal now with the Volume and PRs...
The big OS @RLF but smaller Float could SQQEEEEZE. IMO. Alot of penny shorts here. GEM Rules...
...GLTA...
Yes, also read the fine print. It seems this CONFIRMS RLF patents...
"Dorian Bevec, Ph.D., CSO of AdVita, commented: “We are excited to combine our specific expertise in inhaled formulations of Aviptadil with Relief’s comprehensive scientific catalog of the compound and its uses in respiratory diseases.”
###
ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (Aviptadil), synthetic vasoactive intestinal peptide (VIP), is being developed in collaboration with NeuroRx, Inc. and is currently being investigated in "" two placebo-controlled U.S. phase 2b/3 clinical trials"" in respiratory deficiency due to COVID-19. RLF-100TM is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19."" Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM"".
NRLP...GLTA...
Page 1; NeuroRx recently announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of RLF-100, or “ZYESAMI”, an application for COVID-related respiratory failure (the “NeuroRx COVID-19 Drug”). NeuroRx is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior (the “NeuroRx Antidepressant Drug Regimen”).
The JEWEl of the DEAL IS RLF-100, the other drug is fluff.
Their new product is Much smaller and includes a proprietary PCB and fet-moss chip interface. Look what is all put into a phone.
Safety for the user and Officer was the other concern. Disposable components?
GEM, GEM, GEM...EOM...GLTA...
NeuroRX Agreement to Go Public, in whatever manner, was first disclosed in a NeuroRX PR from October 2019 when it announced GEM Holdings and NeuroRX having negotiated and investor agreement to fund NRX-101.
"HK$ 750 million (USD $96 Million) over a 30 month term following a public listing of NeuroRx's common stock. NeuroRx will use the funds to complete its phase 3 clinical trials and GMP manufacturing requirements in both the US and China for NRX-101"
Then COVID arrived and RLF-100 is NOW the JEWEL of any deal.
About The GEM Group:
Global Emerging Markets ("GEM") is a $3.4 billion alternative investment group based in Paris, New York and Los Angeles. GEM manages a diverse set of investment vehicles focused on emerging markets that provide the group and its investors with a diversified portfolio of asset classes that span the global private investing spectrum. Each investment vehicle has a different degree of operational control, risk-adjusted return and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities (PIPEs) and select venture investments.
Dont know what SoC will be given, but this is from the Trial info. I am willing to wait for well researched results from this interim data..
"Patients qualifying for study enrollment will initiate therapy as outpatients, under home quarantine. Patients will receive continued standard care of therapy (per study site written policies or guidelines) together with bucillamine and/ or matching placebo for up to 14 days. Dosing should continue until the treatment course is completed or as medically indicated (e.g., deterioration of clinical status and alternative therapy required). If the patient requires hospitalization during the study period, treatment will be discontinued."
Sit tight folks. There is Big money invested in VIP. GEM. We're all along for the Ride;
"We dont run the company and can just Buy-Hold-Sell their stock with 'fore sight', 'hind sight' is usually less desirable...
GEM wants this to go to the NASDAQ ASAP. They want a BIG Splash
NRX-101, Emetine, RLF-100 IV and Inhaler...GLTA...
NeuroRX Agreement to Go Public, in whatever manner, was first disclosed in a NeuroRX PR from October 2019 when it announced GEM Holdings and NeuroRX having negotiated and investor agreement to fund NRX-101.
"HK$ 750 million (USD $96 Million) over a 30 month term following a public listing of NeuroRx's common stock. NeuroRx will use the funds to complete its phase 3 clinical trials and GMP manufacturing requirements in both the US and China for NRX-101"
We all know of the GEM investment level here...
This easier to see 'side by side' display from 1-15-21 compared to 1-26-21 shows the New Sites 'highlighted' in the 'Locations' area.
Completion dates are now 'actual'.
The DSMB must have reviewed the Safety Data of the Interim results and told RVV to continue the Phase 3 CT.
The Standard of Care at Different Sites MAY require separate evaluations. Does Buc work better with a specific SOCs? There is also an increasing demand for Patients WILLING to endure the Risks for New treatments. Lots of questions... The company (CRO) is working the Interim data results for those answers along with many other, IMO...GLTA...
https://clinicaltrials.gov/ct2/history/NCT04504734?A=11&B=12&C=Side-by-Side#StudyPageTop
Taking RLF-100 to Market on the Nasdaq is a prime goal, Before Data is released. IMHFO.
NRXP seems to have dropped the ball. They have brought nothing but fluff from JJ and His company leech supposed connections. He PO'ed the DSMB/FDA and created these delays by releasing interim data and not expediting the Trial completion. Have they(NRX) paid bills or set up logistics-sales-OWS-? NO, RLF shareholders/GEM have allowed the progress. RLF owns the JEWEL of any Deal, RLF-100...
GEM wants this /any deal to get this on Nasdaq. ASAP... They want/need the investors/institutions. IMHFO. BEFORE DATA RELEASE, IMHFO...
BTW the urine syrup drug seems to fit the initial purpose of Aviptadil as an ED drug. BRPA was an elderly home investor co. Maybe these can all work out to MOVE FASTESTER. GOOD Data without a future plan may result in a pop and Not the Huge SPLASH we/GEM want...GLTA...
Going to a Nasdaq listing is what makes sense. NRXP hasnt delivered so ACER seems to be the path, ASAP. IMO.
India manufactured Remdesevir for their population without license. They typically dont respect Drug/FDA/WHO rules and do their own thing. Their Trial is just starting and ours has finished and will be presenting data asap. India wont be allowed to sell outside their country just like they couldnt with REM.
There are PLENTY of patients in the countries that The RLF-100 Patent covers.
GEM has recently again supplied RLF with working money. I Think they want RLF-100 going to Market NOW/ASAP/FASTEST/IMMEDIATELY IF POSSIBLE as the pandemic peaks.
RLF has been talking about up=listing for quite a while. I proposed RLF rolling into the NRXP deal due to RLF shareholders owning the Patent for the US (largest market).
NRXP has HAD their opportunity and have NOT delivered a DEAl, for anyone in any form. It's obvious RLF management would seek other possibilities as the delay and lack of proposed inclusion for RL there...
GEM and RLF want some direction for what happens with the "Good Data". IMO.
Announcing going to NASDAQ at the SAME PR and following PUMP WOULD make the Big Splash we all want. IMO...GLTA...
RLF data is due presently and this other Dr reddy trial has just been approved to start.
RLF owns the RLF-100* patent for formulations in the US and several other countries. India is usually an outsider itself and manufactured Remdesivir without license for use in their own country. Currently there is plenty of demand in the countries the patent protection includes.
ACER is perfect for RLF. It would get us out from under the NRX thumb and their issues. The recent new hires at RLf seems to prove JB's point that this is not an unplanned fling and that there are many possibilities that can happen beyond the basic agreement.
Ruf, I hope you know that Aviptadil was an ED drug before repurposing for COVID/lung issues, so why not the drug from Acer that is for a urinary issue too?
*(by whever brand name)
ACER will be a much better vehicle for RLF shareholders, IMO. They have some connections and management perfect for expanding.
NRX/P scamspac is a JJ leech on RLF-100 and this path may be much better, IMO. GEM will have the ball with RLF-100 through the Patents, not JJ and friends.
Time to MOVE FAST is NOW. R/S RLF 1 for 10 and grease the palms with some of the December shares for ACER...Done...
I see some RLF'ers here already.
Time for RLF to shake off the leeches at NRXP and go it alone. ACER could be a good shell to re-merge with for their NASDAQ listing.
RLF-100 is a patented Drug contained in their patents for VIP/RLF-100 formulations and MOA.
1 for 10 RS @ RLF and then use some of the new shares from Dec to seal the deal for ACER holders. Much simpler. Some established connections here at ACER appear much better than BRPA/NRX scamspac...GLTA...
Well, the total 2b/3 CT called for 682 patients and 150 were for the Phase 2b , leaving about 500 for Phase 3. CEO CM mentioned that the cost per patient was about $20k , so I picked $10M. Hope it is less.
My point was there is sufficient money for running Data etc and doing at least Site recruitment and planning with the Warrant money.
I, of course want CEO and S/O to take a couple plane trips carrying an EUA around to some large possible customers and/or partners and Sell that news. ..GLTA...
Correction; If needed maybe raising $10M+ for Phase 3 finances can "THEN" be done at a much better Price. Duh.
CEO CM will work hard for a deal and an EUA will fill his hand. Ours too. IMO...GLTA...
AGN has initially stated the business model as developing the drug, not extended production. Securing 40M doses seems part of the EUA requirement besides suppling the Trials.
Good data may lead to a deal, IMO. If needed maybe raising $10M+ for Phase 3 finances can now be done at a much better Price. The warrants should have supplied enough for the analysis and presentations and-or a flight and hotel near Johnson and Johnson...GLTA...
Kinda also depends on how many sites were involved and where they were located.
Gathering it all together and checking for errors (2-4 weeks), then having a CRO compile the Data ( 1+ weeks).
Then the company scientists will evaluate it all for presentations to the FDA (shareholders, partners, ect) and showing how the Drug did in the Primary and Secondary outcome targets set in the Clinical Trial (1+ weeks). I would assume the DSMB has already passed RLF-100 for safety.
So 4-6+ weeks.
Another Possibility. Section 2...?....GLTA...
https://www.whitehouse.gov/briefing-room/presidential-actions/2021/01/21/executive-order-improving-and-expanding-access-to-care-and-treatments-for-covid-19/
The study of an animal H5N1 Trial is one of the basis for ifenprodil as a COVID treatment. 28 days.?.
I'll wait for the Data and any company plans. I still feel there will not be a PP before their Data presentation. I'm wrong sometimes, though. I've done well with some 'of this group's' stocks. We're all here Now...
COVID came to AGN / Ifenprodil and all/most efforts have followed that direction since for AGN. Micro cap company with pretty much this One big shot. Other repurposed drugs will probably not have this possibility.
I didnt set a Stop at the Interim data either as we all expected stronger trends at that point. Ive actually bought more. I dont see a better possibility even though I own other med stocks.
Maybe some feeling pessimistic should sell before Data or not invest in OTC Gambles. An occasional glass of wine is common. But...JMHFO...
President Biden signed Executive orders for Defense production act and other Agencies to support COVID-19 efforts...GLTA...
President to sign Exec order to support testing, schools, OSHA along with Defense Production Act...About Fkn Time...GLTA...
Gem apparently feels better putting money into running things at RLF. Maybe they wont force a deal like NRLXP could be. (my past thoughts)
A cold shoulder to NRX/P? Maybe they're tired of the BS and realize RLF has the patents, Is developing logistics and manufacturing NOW, etc.
Main sales are to USA, SA and some EU. What do they need the leech factor of NRX for anymore? NRX is NOT putting ANYTHING into the partnership.?. Dr JJ floff for HIS company and buddies???
From the 'Last patient out PR..."All development costs under the agreement are paid by Relief, providing NeuroRx with non dilutive development capital through drug approval"
Zyesami" Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM". Now including Inhaler?...
My past thoughts were this,
"NRXP will need to settle the ownership of RLF-100 for their deal. Lawsuits question NRXP deal for High price and no control of RLF-100"...
BUT
Why carry their ball and for WHAT?
My point is this pays bills until Data. If cash is needed. Then.?.
CM wanted a strong hand to play from the Interim Data, maybe Ifenprodil can still deliver at 28. Nothing is significantly beating SOC.?.
Even the H5N1 murine trials went to 28 days for those results.
Calling the warrants brings in cash to operate until Data?
https://finance.yahoo.com/news/algernon-pharmaceuticals-provides-reminder-expiry-170000212.html
The areas in most Need ('Market') are mainly in the USA and South America for RLF-100. Brand names don't change Patent rights...GLTA...
BTW, I don't think anything posted on IHub MBs affect the 11M shares traded. Venting and Free Speech supporting an opinion require facts to be taken seriously...
RLF and NRXP both need to be very careful in PRs right now just before data for RLF-100 is released. We dont need a leak/investigation but Patients can release personal stories though.
IMO the Biggest Splash = Good+ data for RLF-100 > EUA > RS > RLNXP with PROPER International Fan fair/Hype/PUM/.P/ to NASDAQ. Combined management would be better for logistics/sales/etc. Faster everything. NRXP needs the Patent.. *130M-OS (30M to nrxp) @ $30, then Possible F/S in 60 -120 days, imo.
Second would be Good+ data for RLF-100 > EUA > then with PROPER International Fan fair/Hype/PUMP/ RLF to the NASDAQ. A path for RLF.SW (?) RLFTF to NASDAQ might be slower. RLF has subcontracting and partnership plans but has depended on NRX.?. *3.2B-OS @ <$2, then INHALER 60 + days ?
From the 'Last Patient Out PR... gota mean something?
"All development costs under the agreement are paid by Relief, providing NeuroRx with non dilutive development capital through drug approval"
"Zyesami"
"Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM"
Well, all the other current treatments are barely beating SOC and most have adverse Safety issues.
Realistic Secondary Outcomes at day 28 are still to come for the COVID Trial and a Phase 3 is still the Company Plan. Time to On/Off Ventilation, hospitalization and longer term recoveries stated by the company PRs..
Evaluation as a combination of treatments used in different Trial sites is also being done. A Realistic Goal for Ifenprodil was always as part of a solution, not a wizbang endall.
Younger people are becoming a larger part of the cases. Vaccinations will take time. Huge Markets for reasonable success... Trips to Marz or complete scam defeatism are about the same chances.
I'll go with an effective "Cocktail" Concept...GLTA...
Opinion assisted by 4spirits distillery.
I'm mainly saying RLF shareholders paid for RLF-100 and Own the Patent rights for the formulations. RLF-100 is the "JEWEL" for Severe COVID patient recovery.
I hope for an EUA.
I hope RLF may be part of NRXP, soon(NRLXP).
I have recently re-read some info on Primary and Secondary Outcomes from Clinical Trials related to COVID-19.
There are few with the High Goals Set by RLF-100 (Or by whatever Brand name)... None with Interim Data matching RLF-100.
Some are weak and/or using shotguns picking 'outcome' targets.
Most treatments have had harmful side effects besides being relatively ineffective. Data and Patient successes have been meager, barely surpassing SOC.
Yes, RLF shareholders have suffered serious dilution paying for 'Development' of RLF-100, BUT we still own the PATENT. That's the JEWEL of Any Deal and Any future Manufacturing / Distribution / Sales Partnerships. IMO.
All development costs under the agreement are paid by Relief, providing NeuroRx with non dilutive development capital through drug approval"
Zyesami"
Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM"...
formulations = INHALER...
God Bless MLK and his Legacy.
...GLTA...